Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Comment by Laine1on May 28, 2010 7:05am
586 Views
Post# 17139292

Stem Cells - Clarification

Stem Cells - ClarificationNot to belabour the point....but we need to clarify what we are talking about here... neural stem cell proliferation was discovered in 1990 not the 1970's. These clinical trials are based on the subsequent proof of principal studies confirmed in the last decade so we are not talking about a 40 year lag as your post suggests. Also, EPO is secondary to hCG in these  trials -  hCG is the primary agent that promotes mobilization of neural stem cells. Lastly, this therapy involves mobilizing resident stem cells, not transplantation.
Bullboard Posts